StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)

Close on Nov 18, 2026Market cap $62.83KP/E –Yield –

Earnings

Addex Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Addex Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Apr 30, 2026before the open–––Release
Q4 FY2024ended Dec 31, 2024Apr 25, 2025before the open–––Release
Q4 FY2023ended Dec 31, 2023Apr 18, 2024before the open–––Release
Q4 FY2022ended Dec 31, 2022Mar 30, 2023before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 10, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Addex Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Addex Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Addex Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?